Akari Therapeutics PLC ADR AKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $15.84
- Day Range
- $14.01–16.10
- 52-Week Range
- $3.02–52.20
- Bid/Ask
- $14.06 / $15.60
- Shares Outstanding
- 1.57M
- Market Cap
- $17.25M
- Volume/Avg
- 228 / 742,664
Key Statistics
- Price/Earnings (Normalized)
- 0.77
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 5
- Website
- https://www.akaritx.com
Valuation
|
Metric
|
AKTX
|
|---|---|
Price/Earnings (Normalized) | 0.77 |
Price/Book Value | 1.20 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AKTX
Financial Strength
|
Metric
|
AKTX
|
|---|---|
Quick Ratio | 0.21 |
Current Ratio | 0.27 |
Interest Coverage | −30.32 |
Quick Ratio
AKTX
Profitability
|
Metric
|
AKTX
|
|---|---|
Return on Assets (Normalized) | −16.47% |
Return on Equity (Normalized) | −33.46% |
Return on Invested Capital (Normalized) | −27.52% |
Return on Assets
AKTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Rcsdzpfc | Bwtwfg | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Scpvtqsj | Spgkkh | $67B | |||
| argenx SE ADR
ARGX
| Drshyhtpn | Zzh | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yjtcdhlkl | Czflf | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Sgzwzfknq | Rvglkj | $25B | |||
| BioNTech SE ADR
BNTX
| Pymdsmbjd | Mqmt | $22B | |||
| Incyte Corp
INCY
| Bklvsbwj | Frbd | $20B | |||
| Moderna Inc
MRNA
| Pmbrtpv | Ffsm | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Qbwrkxyc | Sglwr | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Yhvmmlj | Dfxk | $13B |
United States